Company Update (NYSE:PFE): Sosei Subsidiary Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. Focused on GPCR Targets Across Multiple Therapeutic Areas

[Business Wire] – TOKYO–(BUSINESSWIRE)– Sosei Group Corporation (“Sosei”) (TOKYO:4565) today announces that its wholly-owned subsidiary, Heptares Therapeutics has entered into a strategic drug discovery collaboration with Pfizer Inc. (NYSE:PFE – News) to research . . . → Read More: Company Update (NYSE:PFE): Sosei Subsidiary Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. Focused on GPCR Targets Across Multiple Therapeutic Areas Similar Articles: Company Update: Pfizer Inc (NYSE:PFE) – Pfizer Announces Collaboration with GSK on Next-Generation Design of Portable, Continuous, Miniature and Modular (PCMM) Oral Solid Dose Development and Manufacturing Units Company Update: Pfizer Inc (NYSE:PFE) – Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder Company Update: Pfizer Inc (NYSE:PFE) – Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D